Complex Cannabinoid Mixtures for Treating Neurodegenerative Diseases
GBS Global BioPharma Inc. of Ontario, Canada received a patent (US Pat. No. 10,653,640) this week for a complex cannabinoid mixture for treating neurodegenerative diseases like Alzheimer’s and Parkinson’s disease.
A main cannabinoid (CBD or CBN) is mixed with a minor cannabinoid (cannabichromene, cannabigerol, and cannabidivarin) and terpenes (limonene, linalool, nerolidol, pinene, and phytol) along with a pharmaceutically acceptable carrier.
Cannabinoids can target mechanistic pathways of Parkinson’s disease as well as have beneficial effects on the mitochondria by acting as an antioxidant and decreasing oxidative stress.
The therapeutic benefits of cannabinoids are still being studied and harnessed. Take a look at patents and patent applications for cannabinoid supplements and medications with a subscription to Magic Number’s Cannabis Patent Forecast®.
Related Posts
Cannabis Popularity Soars Along With Tests To Detect It
The Duquenois Levine Test is used in the field by law enforcement officers to test for THC presence in a suspected sample. The problem with…
Hound Labs, Cannabix and Vox Heat Up the Marijuana Breathalyzer Market
At the start of April 2021, Patent Forecast® released an insight going over some of the big name competitors getting their foot in the door…
Driving While High? Cannabis Sobriety Testing Heats Up
What’s the future of cannabis innovation? We see things before they happen using our Patent Forecast®. One of those is the development of…